Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
86.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
22
22 articles ont été cités au moins 22fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 422
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
110
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
38
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Intercommunal de Poissy
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis
2026ArticleNeurology
External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database
2026ArticleMultiple Sclerosis and Related Disorders
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study
2026ArticleCNS Drugs
Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis
2026ArticleBrain - A Journal of Neurology
Specific procedure combinations in a rehabilitation setting define severity clusters of older adults with multiple sclerosis: a cohort study
2026ArticleAnnals of Physical and Rehabilitation Medicine
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis
2026ArticleJournal of Neurology, Neurosurgery and Psychiatry
Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in France
2025ArticleBMC Neurology
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis
2025ArticleJAMA neurology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET PRIVE DU DR OLIVIER HEINZLEF
HOPITAL DE POISSY 10 RUE DU CHAMP GAILLARD B.P. 3082, 78303 POISSY CEDEX
CHI POISSY ST GERMAIN SITE DE POISSY
10 R DU CHAMP GAILLARD BP 3082, 78303 POISSY CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
JAMA · 2025
ImportanceVitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting.ObjectiveTo evaluate the efficacy of high-dose cholecalciferol as monotherapy in reducing disease activity in patients with clinically isolated syndrome (CIS) typical for MS.Design, Setting, and ParticipantsThe D-Lay MS trial was a parallel, double-blind, randomized placebo-controlled clinical trial in 36 MS centers in France. Patients were enrolled from July 2013 to December 2020 (final follow-up on January 18, 2023). Untreated patients with CIS aged 18 to 55 years with CIS duration less than 90 days, serum vitamin D concentration less than 100 nmol/L, and diagnostic magnetic resonance imaging (MRI) meeting 2010 criteria for dissemination in space or 2 or more lesions and presence of oligoclonal bands were recruited.InterventionPatients were randomized 1:1 to receive oral cholecalciferol 100 000 IU (n = 163) or placebo (n = 153) every 2 weeks for 24 months.Main Outcomes and MeasuresThe primary outcome measure was disease activity, defined as occurrence of a relapse and/or MRI activity (new and/or contrast-enhancing lesions) over 24 months of follow-up, also analyzed as separate secondary outcomes.ResultsOf the 316 participants enrolled and randomized (median [IQR] age, 34 [28-42] years; 70% women), the primary analysis included 303 patients (95.9%) who took at least 1 dose of the study drug and 288 (91.1%) ultimately completed the 24-month trial. Disease activity was observed in 94 patients (60.3%) in the vitamin D group and 109 patients (74.1%) in the placebo group (hazard ratio [HR], 0.66 [95% CI, 0.50-0.87]; P = .004), and median time to disease activity was longer in the vitamin D group (432 vs 224 days; log-rank P = .003). All 3 secondary MRI outcomes reported significant differences favoring the vitamin D group vs the placebo group: MRI activity (89 patients [57.1%] vs 96 patients [65.3%]; HR, 0.71 [95% CI, 0.53-0.95]; P = .02), new lesions (72 patients [46.2%] vs 87 patients [59.2%]; HR, 0.61 [95% CI, 0.44-0.84]; P = .003), and contrast-enhancing lesions (29 patients [18.6%] vs 50 patients [34.0%]; HR, 0.47 [95% CI, 0.30-0.75]; P = .001). All 10 secondary clinical outcomes showed no significant difference, including relapse, which occurred in 28 patients (17.9%) in the vitamin D group vs 32 (21.8%) in the placebo group (HR, 0.69 [95% CI, 0.42-1.16]; P = .16). Results were similar in a subset of 247 patients meeting updated 2017 diagnostic criteria for relapsing-remitting MS at treatment initiation. Severe adverse events occurred in 17 patients in the vitamin D group and 13 in the placebo group, none of which were related to cholecalciferol.Conclusions and RelevanceOral cholecalciferol 100 000 IU every 2 weeks significantly reduced disease activity in CIS and early relapsing-remitting MS. These results warrant further investigation, including the potential role of pulse high-dose vitamin D as add-on therapy.Trial RegistrationClinicalTrials.gov Identifier: NCT01817166
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Neurology · 2026 · Journal Article
Gavoille A, Kerbrat A, Edan G, Le Page E, et al.
Brain : a journal of neurology · 2026 · Journal Article
Rollot F, Casey R, Kerbrat A, Edan G, et al.
Neurology · 2025 · Journal Article
Gavoille A, Leray E, Marignier R, Rollot F, et al.
Neurology · 2025 · Journal Article
Robin C, Rollot F, Lefort M, Casey R, et al.
European journal of neurology · 2025 · Journal Article
Cohen M, Rollot F, Debouverie M, Zephir H, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2025 · Journal Article
Lefort M, Dejardin O, Berger E, Camdessanché JP, et al.
Neurology · 2024 · Journal Article
Hay M, Rollot F, Casey R, Kerbrat A, et al.
Neuroradiology · 2024 · Journal Article
Federau C, Hainc N, Edjlali M, Zhu G, et al.
Neurology · 2022 · Observational Study
Roos I, Malpas C, Leray E, Casey R, et al.
BMC medical research methodology · 2021 · Journal Article
Thurin NH, Bosco-Levy P, Blin P, Rouyer M, et al.
JAMA neurology · 2020 · Journal Article
Louapre C, Collongues N, Stankoff B, Giannesini C, et al.
Journal of the neurological sciences · 2020 · Journal Article
Ouallet JC, Radat F, Creange A, Abdellaoui M, et al.
Behavioural brain research · 2018 · Journal Article
Abidi M, Bruce J, Le Blanche A, Bruce A, et al.
CNS drugs · 2026 · Journal Article
Roos I, Sharmin S, Ozakbas S, Alroughani R, et al.
Annals of physical and rehabilitation medicine · 2026 · Journal Article
Levy J, Leilaz A, Léotard A, Joussain C, et al.
Journal of neurology, neurosurgery, and psychiatry · 2026 · Journal Article
Gavoille A, Nourredine M, Rollot F, Casey R, et al.
Advances in therapy · 2025 · Journal Article
de Sèze J, Labauge P, Liblau R, Martinez M, et al.
Neurology and therapy · 2025 · Journal Article
Labauge P, Créange A, Moreau T, Nouvet-Gire J, et al.
Journal of neurology, neurosurgery, and psychiatry · 2024 · Randomized Controlled Trial
Gay MC, Cassedanne F, Barbot F, Vaugier I, et al.
Journal of neurology, neurosurgery, and psychiatry · 2026 · Journal Article
Gavoille A, Nourredine M, Rollot F, Casey R, et al.
JAMA · 2025 · Clinical Trial, Phase III
Thouvenot E, Laplaud D, Lebrun-Frenay C, Derache N, et al.
Journal of neurology, neurosurgery, and psychiatry · 2024 · Randomized Controlled Trial
Frontiers in psychology · 2021 · Journal Article
Torkhani E, Dematte E, Slawinski J, Csillik A, et al.
PharmacoEconomics - open · 2020 · Journal Article
Heinzlef O, Molinier G, van Hille B, Radoszycki L, et al.
Journal of neuroradiology = Journal de neuroradiologie · 2026 · Journal Article
Mastilović M, Muños-Ramírez V, Rauschecker AM, Boban J, et al.
JAMA neurology · 2024 · Journal Article
Gavoille A, Rollot F, Casey R, Kerbrat A, et al.
JAMA neurology · 2024 · Journal Article
Benallegue N, Rollot F, Wiertlewski S, Casey R, et al.
Patient preference and adherence · 2018 · Journal Article
Mékiès C, Heinzlef O, Jenny B, Ramelli AL, et al.
Journal of neurology, neurosurgery, and psychiatry · 2024 · Randomized Controlled Trial
Gay MC, Cassedanne F, Barbot F, Vaugier I, et al.
Determinants of therapeutic lag in multiple sclerosis
Background:A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups.Objectives:The objective of this study is to explore the associations o
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Background:Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021.Objectives:We aimed to extend these data
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Background:Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021.Objectives:We aimed to extend these data
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study
Background:Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy.Objective:To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 1
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study
Background:Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy.Objective:To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 1
Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data
Abstract Background Diagnosis performances of case-identifying algorithms developed in healthcare database are usually assessed by comparing identified cases with an external data source. When this is not feasible, intra
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
The Lancet regional health. Europe · 2023 · Journal Article
Wilson S, Calocer F, Rollot F, Fauvernier M, et al.
Multiple sclerosis and related disorders · 2021 · Journal Article
Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, et al.
JAMA neurology · 2020 · Journal Article
Vukusic S, Rollot F, Casey R, Pique J, et al.
British journal of clinical pharmacology · 2022 · Journal Article
Bosco-Lévy P, Debouverie M, Brochet B, Guillemin F, et al.
Multiple sclerosis and related disorders · 2021 · Journal Article
Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, et al.
Neurology · 2019 · Comparative Study
Laplaud DA, Casey R, Barbin L, Debouverie M, et al.
Gay MC, Cassedanne F, Barbot F, Vaugier I, et al.
Frontiers in psychology · 2021 · Journal Article
Torkhani E, Dematte E, Slawinski J, Csillik A, et al.
CNS drugs · 2018 · Journal Article
Tourbah A, Gout O, Vighetto A, Deburghgraeve V, et al.